Asceneuron Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 10

Asceneuron General Information

Description

Developer of therapeutic compounds designed to treat neurodegenerative disorders. The company focuses on developing treatments for a wide range of neurodegenerative diseases, including orphan tauopathies, Alzheimer's, and Parkinson's disease, enabling medical professionals to access suitable therapies to improve the lives of patients affected by neurodegenerative diseases.

Contact Information

Website
www.asceneuron.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Route de Crassier 7
  • 1262 Eysins
  • Switzerland
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Route de Crassier 7
  • 1262 Eysins
  • Switzerland

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Asceneuron Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Secondary Transaction - Private Completed Clinical Trials - Phase 1
7. Later Stage VC (Series C) 16-Jul-2024 Completed Clinical Trials - Phase 1
6. Debt - General 30-Mar-2022 Completed Clinical Trials - Phase 1
5. Grant 09-Mar-2021 Completed Clinical Trials - Phase 1
4. Early Stage VC (Series A) 29-Sep-2015 Completed Clinical Trials - Phase 1
3. Grant 09-Apr-2015 Completed Startup
2. Seed Round 02-Oct-2012 $6.44M $6.44M Completed Startup
1. Accelerator/Incubator Completed Startup
To view Asceneuron’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Asceneuron Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of therapeutic compounds designed to treat neurodegenerative disorders. The company focuses on developing trea
Drug Discovery
Eysins, Switzerland
9 As of 2026

Lyon, France
 

Reinach, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Asceneuron Competitors (96)

One of Asceneuron’s 96 competitors is ENYO Pharma, a Venture Capital-Backed company based in Lyon, France.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ENYO Pharma Venture Capital-Backed Lyon, France
SunRegen Venture Capital-Backed Reinach, Switzerland
Sangamo Therapeutics Formerly VC-backed Richmond, CA
NeuroNascent Venture Capital-Backed Clarksville, MD
Rewind Therapeutics Venture Capital-Backed Leuven, Belgium
You’re viewing 5 of 96 competitors. Get the full list »

Asceneuron Patents

  • 119

    Total Documents Applications and Grants

  • Total Patents Families

  • 78

    Granted

  • 10

    Pending

  • Expiring in next 12 mo

Asceneuron Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023477048-A1 (2-(4-(1-(benzo[d]thiazol-5-yl)ethyl)piperazin-1 -yl)pyrimidin-5-yl)(imino)(methyl)-lamda6-sulfanone for use in the treatment of colitis, parkinson disease, tauopathy, als and alzheimer's disease Pending 20-Dec-2023
EP-4827858-A1 (2-(4-(1-(benzo[d]thiazol-5-yl)ethyl)piperazin-1 -yl)pyrimidin-5-yl)(imino)(methyl)-lamda6-sulfanone for use in the treatment of colitis, parkinson disease, tauopathy, als and alzheimer's disease Pending 20-Dec-2023
WO-2025131275-A1 (2-(4-(1-(benzo[d]thiazol-5-yl)ethyl)piperazin-1 -yl)pyrimidin-5-yl)(imino)(methyl)-lamda6-sulfanone for use in the treatment of colitis, parkinson disease, tauopathy, als and alzheimer's disease Inactive 20-Dec-2023
AU-2021455177-A1 Medicaments comprising glycosidase inhibitors Active 05-Jul-2021
AU-2021455177-B2 Medicaments comprising glycosidase inhibitors Active 05-Jul-2021 A61K31/496
To view Asceneuron’s complete patent history, request access »

Asceneuron Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Asceneuron Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
EQT Life Sciences Venture Capital Minority
GSK Corporation Minority
Merck Serono Corporation Minority
Novo Holdings Venture Capital Minority
OrbiMed Growth/Expansion Minority
You’re viewing 5 of 10 investors. Get the full list »

Ready to get started?

Request a free trial

Asceneuron FAQs

  • When was Asceneuron founded?

    Asceneuron was founded in 2012.

  • Where is Asceneuron headquartered?

    Asceneuron is headquartered in Eysins, Switzerland.

  • What is the size of Asceneuron?

    Asceneuron has 9 total employees.

  • What industry is Asceneuron in?

    Asceneuron’s primary industry is Drug Discovery.

  • Is Asceneuron a private or public company?

    Asceneuron is a Private company.

  • What is Asceneuron’s current revenue?

    The current revenue for Asceneuron is .

  • How much funding has Asceneuron raised over time?

    Asceneuron has raised $138M.

  • Who are Asceneuron’s investors?

    EQT Life Sciences, GSK, Merck Serono, Novo Holdings, and OrbiMed are 5 of 10 investors who have invested in Asceneuron.

  • Who are Asceneuron’s competitors?

    ENYO Pharma, SunRegen, Sangamo Therapeutics, NeuroNascent, and Rewind Therapeutics are some of the 96 competitors of Asceneuron.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process